These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16857665)

  • 1. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.
    Harikumar KG; Pinon DI; Miller LJ
    J Biol Chem; 2006 Sep; 281(37):27072-80. PubMed ID: 16857665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
    Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
    J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor.
    Harikumar KG; Hosohata K; Pinon DI; Miller LJ
    J Biol Chem; 2006 Feb; 281(5):2543-50. PubMed ID: 16319066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.
    Harikumar KG; Gao F; Pinon DI; Miller LJ
    Biochemistry; 2008 Sep; 47(36):9574-81. PubMed ID: 18700727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
    J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth.
    Cheng ZJ; Harikumar KG; Holicky EL; Miller LJ
    J Biol Chem; 2003 Dec; 278(52):52972-9. PubMed ID: 14534299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Miller LJ
    Biosci Rep; 2006 Apr; 26(2):89-100. PubMed ID: 16779661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
    Harikumar KG; Cawston EE; Lam PCH; Patil A; Orry A; Henke BR; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Biol Chem; 2013 Jul; 288(29):21082-21095. PubMed ID: 23754289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG; Miller LJ
    J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
    Cawston EE; Harikumar KG; Miller LJ
    Am J Physiol Cell Physiol; 2012 Feb; 302(3):C615-27. PubMed ID: 22049215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Fluorescence Indicators in Receptor Ligands.
    Harikumar KG; Miller LJ
    Methods Mol Biol; 2015; 1335():115-30. PubMed ID: 26260598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
    Dong M; Lam PC; Pinon DI; Abagyan R; Miller LJ
    Biochemistry; 2009 Jun; 48(23):5303-12. PubMed ID: 19441839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z; Hadac EM; Henne RM; Patel SA; Lybrand TP; Miller LJ
    J Biol Chem; 1997 Sep; 272(39):24393-401. PubMed ID: 9305898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58.
    Reeve JR; McVey DC; Bunnett NW; Solomon TE; Keire DA; Ho FJ; Davis MT; Lee TD; Shively JE; Vigna SR
    Pancreas; 2002 Oct; 25(3):e50-5. PubMed ID: 12370550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
    Dong M; Hadac EM; Pinon DI; Miller LJ
    Mol Pharmacol; 2005 Jun; 67(6):1892-900. PubMed ID: 15774770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis.
    Dong M; Ding XQ; Pinon DI; Hadac EM; Oda RP; Landers JP; Miller LJ
    J Biol Chem; 1999 Feb; 274(8):4778-85. PubMed ID: 9988716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.
    Harikumar KG; Potter RM; Patil A; Echeveste V; Miller LJ
    Lipids; 2013 Mar; 48(3):231-44. PubMed ID: 23306829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.